- Home
- CTNM vs PRTA Comparison
CTNM vs PRTA Comparison
Compare CTNM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNM | PRTA |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 495.8M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTNM | PRTA |
|---|---|---|
| Price | $11.68 | $9.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $18.60 | ★ $18.86 |
| AVG Volume (30 Days) | 234.6K | ★ 688.5K |
| Earning Date | 03-05-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $4.32 |
| 52 Week High | $13.49 | $16.67 |
Technical Indicators
Market Signals| Indicator | CTNM | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 49.39 |
| Support Level | $11.00 | $8.65 |
| Resistance Level | $12.29 | $9.55 |
| Average True Range (ATR) | 0.86 | 0.39 |
| MACD | 0.22 | 0.06 |
| Stochastic Oscillator | 96.21 | 74.52 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.